A Phase II study (Study 39, D0810C00039; NCT01063517) showed that the oral PARP inhibitor olaparib (Lynparza) combined with paclitaxel provided a statistically significant improvement in overall survival (OS) versus paclitaxel alone as second-line therapy in Asian patients (pts) with advanced gastric cancer. A greater OS benefit was seen in pts whose tumour was ATM protein negative by immunochemistry (ATM–). ATM is a key sensor of the DNA damage response pathway. We report final analyses from a subsequent Phase III study (GOLD, D081BC00004; NCT01924533). GOLD evaluated the efficacy and safety of olaparib (100 mg tablet bid, continuous) in combination with paclitaxel (80 mg/m2 iv on days 1, 8, 15 per 28-day cycle) (O/P) compared with placebo in combination with paclitaxel (P/P).
Pts were randomized 1:1 to O/P or P/P and treated until progression (RECIST 1.1), unmanageable toxicity or consent withdrawal. On discontinuation of paclitaxel (without progression), olaparib (300 mg bid) or placebo was given as monotherapy. The co-primary endpoints were OS for all pts (full analysis set [FAS]) and ATM– pts. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR) and safety.
521/525 randomized pts were treated (O/P = 261; P/P = 260), including 93/94 ATM– pts (O/P = 47; P/P = 46).
|All pts (FAS) (72.6% OS maturity)||N = 263||N = 262|
|Median OS, months||8.8||6.9||HR = 0.79; 97.5% CI 0.63, 1.00; P = 0.0262|
|Median PFS, months||3.7||3.2||HR = 0.84; 97.5% CI 0.67, 1.04; P = 0.0645|
|Adjusted ORR,* %||24.0||15.8||OR = 1.69; 97.5% CI 0.92, 3.17; P = 0.0548|
|ATM– pts (68.1% OS maturity)||n = 48||n = 46|
|Median OS, months||12.0||10.0||HR = 0.73; 97.5% CI 0.40, 1.34; P = 0.2458|
|Median PFS, months||5.3||3.7||HR = 0.74; 97.5% CI 0.45, 1.29; P = 0.2199|
|Adjusted ORR,* %||37.5||16.1||OR = 4.24; 97.5% CI 0.95, 23.23; P = 0.0309|
Due to Hochberg multiple testing procedure, statistical significance was P < 0.025 for each population *Response rate in pts with measurable disease only CI, confidence interval; HR, hazard ratio; OR, odds ratio HR 1 favours O/P; P values are two sided.In the O/P and P/P arms, respectively, grade ≥3 adverse events (AEs) were reported in 78% and 62% of pts, most frequently neutropenia (30% vs 23%). Serious AEs were reported in 35% and 25% of pts, and AEs leading to discontinuation occurred in 16% and 10% of pts.
A trend towards OS benefit, independent of ATM status, was observed for O/P compared with P/P in the FAS. O/P did not provide statistically significant increased OS, PFS or ORR in the FAS or ATM– pts compared with P/P. O/P followed by olaparib monotherapy was well tolerated with no new safety signals.
Clinical trial identification
D081BC00004; NCT01924533 2 May 2013
Legal entity responsible for the study
Y-J. Bang: I received research funds from AstraZeneca (through my institution), and I have consulted AstraZeneca. L. Shen: Personal fees received from: Hengrui Taiho Roche Novartis. S-A. Im: Research grant from AstraZeneca. G. Locker, X. Shi, D. Hodgson, Y-Z. Liu: AstraZeneca employee and own AstraZeneca stock. P. Rowe: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.